CRM vs DHR: Which Is the Better Buy?
Side-by-side comparison of Salesforce, Inc. and Danaher Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Salesforce, Inc. · Technology
$151.78
+45.0% upside to fair value
Grade A
High Quality
VS
Danaher Corporation · Healthcare
$177.17
+8.9% upside to fair value
Grade B
High Quality
QuantHub Verdict
CRM has more upside to fair value
(+45.0%).
CRM trades at a lower forward P/E
(17.5x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRM |
DHR |
| Current Price |
$151.78 |
$177.17 |
| Fair Value Estimate |
$220.08 |
$192.90 |
| Upside to Fair Value |
+45.0%
|
+8.9%
|
| Market Cap |
$124.3B |
$125.4B |
| Forward P/E |
17.5x
|
34.1x
|
| EV / EBITDA |
11.2x
|
20.8x
|
| Price / Sales |
2.9x
|
5.1x
|
| Price / FCF |
8.5x
|
23.7x
|
| Revenue Growth YoY |
+13.3%
|
+3.7%
|
| Gross Margin |
77.6%
|
60.7%
|
| Operating Margin |
21.9%
|
21.0%
|
| Return on Equity |
14.9%
|
7.1%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
11.79%
|
4.22%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Salesforce, Inc. is a leading enterprise software company specializing in customer relationship management (CRM) and cloud-based applications. The company benefits from a durable competitive moat driven by a dominant global CRM market share in the mid-20% range, stable to slightly widening over the past decade. Under founder-CEO Marc Benioff's leadership, Salesforce has grown to $41.5 billion in …
Danaher Corporation operates in the healthcare sector, specializing in medical diagnostics and research tools through three balanced platforms: Biotechnology, Life Sciences, and Diagnostics. The company benefits from a durable competitive moat supported by the Danaher Business System, disciplined capital allocation, and a platform-centric organizational structure. Despite modest revenue growth of…
Accumulation Zones
| Metric |
CRM |
DHR |
| Zone Low |
$165.06 |
$144.68 |
| Zone High |
$187.07 |
$163.97 |
| In Buy Zone? |
Yes
|
No
|